| Line Item | 2022-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $179.3M | +41.1% |
| SG&A Expense | $49.7M | +29.9% |
| Operating Income | -$228.0M | -37.9% |
| Net Income | -$221.1M | -33.9% |
| EPS (Basic) | -$5.32 | -7.9% |
| EPS (Diluted) | -$5.32 | -7.9% |
| Line Item | 2022-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $121.2M | -9.1% |
| Short-term Investments | $305.9M | +218.0% |
| Current Assets | $438.4M | +82.1% |
| Total Assets | $513.5M | +72.2% |
| Current Liabilities | $44.7M | +60.9% |
| Total Liabilities | $226.2M | +325.1% |
| Stockholders' Equity | $287.3M | +17.3% |
| Line Item | 2022-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$5.9M | +95.3% |
| Capital Expenditures | $10.2M | -22.9% |
| Investing Cash Flow | -$225.6M | -1622.8% |
| Financing Cash Flow | $219.4M | +8760.3% |
| Free Cash Flow | -$16.1M | +88.3% |